Buzzkill Labs
- 18/05/2023
- Series A
- Undisclosed Amount
Buzzkill Labs is modernizing drug testing for a world of legal cannabis. We are developing and commercializing portable, rapid, cost-effective testing of oral fluid (saliva) that distinguishes and measures THC parent compound, the psychoactive component of cannabis that causes impairment. Our technology helps to eliminate cheating and to determine current potential impairment versus past use with no interference from CBD or metabolites in 15 minutes.
- Industry Biotechnology Research
- Website https://www.buzzkilllabs.com/
- LinkedIn https://www.linkedin.com/company/buzzkill-labs/
Related People
Jeff HeimburgerFounder
Accomplished commercial executive who's knowledge spans marketing, sales, business development, product development and commercial operations. Jeff leads teams in the development and execution of product portfolio and commercial strategies, achieving results both organically and through partnership or M&A.
PROFESSIONAL EXPERIENCE
BUZZKILL LABS, INC.
CEO
INDEPENDENT CONSULTANT
Principal
AGILENT TECHNOLOGIES, INC.
Head of Marketing, Genomics
INTEGENX, INC. (now part of Thermo Fisher Scientific)
Vice President, Marketing
FOCUS DIAGNOSTICS, INC. (then a subsidiary of Quest Diagnostics, now part of DiaSorin Group)
Senior Director, Global Marketing
PATH4WARD, INC.
co-Founder
ROCHE MOLECULAR SYSTEMS, INC.
International Business Leader
Director of Global Marketing & Business Development
APPLIED IMAGING CORP (now part of Leica Microsystems, a Danaher business)
Director of Worldwide Marketing
ABBOTT LABORATORIES
Program Manager, New Product Development
Manager, Technical Product Services
Worldwide Marketing Senior Product Manager
Worldwide Marketing Product Manager
Major Account Executive
Diagnostic Systems Specialist
DOW CORNING CORPORATION
Technical Sales Representative
SPECIALTIES:
Strategy development and execution
Team building and organizational leadership
Commercial operations in life sciences and medical devices